Literature DB >> 8219449

Evaluation of pharmacoeconomic studies: utilization of a checklist.

J A Sacristán1, J Soto, I Galende.   

Abstract

OBJECTIVE: To review the fundamental concepts used in clinical economic analysis and establish a simple model to systematically evaluate the quality of pharmacoeconomic studies. DATA SOURCES: A MEDLINE search was used to identify pertinent pharmacoeconomic literature, including reviews. STUDY SELECTION: Selected literature evaluating the methodology of health economics studies was used.
CONCLUSIONS: The number of studies presenting a pharmacoeconomic evaluation has increased progressively; however, the quality of the studies has not improved in parallel. The existence of different types of pharmacoeconomic studies does not justify their arbitrary use and the achievement of valid conclusions must be based on sound knowledge of the concepts employed, as well as on use of the most adequate tool in each instance. By evaluating pharmacoeconomic studies systematically, the more common errors (i.e., in planning the study or interpreting the results) can be detected and thus prevented. The checklist we present has 12 sections, each of which includes several subsections. After evaluating the corresponding subsections, each section is labeled as "correct," "acceptable," "doubtful," "incorrect," or "not applicable." From this qualitative evaluation, aspects that have been dealt with correctly and those needing improvement will become apparent. Also, the checklist permits the user to verify whether the results have been correctly obtained and, therefore, whether the conclusions are valid. The use of a checklist for evaluating pharmacoeconomic studies may be useful for researchers, journal editors, and the audience when performing, receiving, reading, or accepting a clinical economic study.

Mesh:

Year:  1993        PMID: 8219449     DOI: 10.1177/106002809302700919

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  14 in total

Review 1.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

Review 2.  The effect of managed care on prescription drug costs and benefits.

Authors:  A Lyles; F B Palumbo
Journal:  Pharmacoeconomics       Date:  1999-02       Impact factor: 4.981

3.  Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

Authors:  M Iskedjian; K Trakas; C A Bradley; A Addis; K Lanctôt; D Kruk; A L Ilersich; T R Einarson
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 4.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

5.  Pharmacoeconomics and formulary decision making.

Authors:  L A Sanchez
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

6.  A monograph assignment as an integrative application of evidence-based medicine and pharmacoeconomic principles.

Authors:  Anandi V Law; Cynthia A Jackevicius; Mark Bounthavong
Journal:  Am J Pharm Educ       Date:  2011-02-10       Impact factor: 2.047

7.  Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists.

Authors:  Michael J Zoratti; A Simon Pickard; Peep F M Stalmeier; Daniel Ollendorf; Andrew Lloyd; Kelvin K W Chan; Don Husereau; John E Brazier; Murray Krahn; Mitchell Levine; Lehana Thabane; Feng Xie
Journal:  Eur J Health Econ       Date:  2021-04-11

8.  Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones.

Authors:  K M Jensen; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

Review 9.  The pharmacoeconomics of dementia therapies. Bringing the clinical, research and economic perspectives together.

Authors:  F J Molnar; W B Dalziel
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

10.  Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study.

Authors:  J A Sacristán; J C Gómez; J Martín; E García-Bernardo; V Peralta; E Alvarez; M Gurpegui
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.